Castration-Resistant Prostate Carcinoma

Castration-Resistant Prostate Carcinoma — Drugs · CancerIndex

Regulatory

Approvals by jurisdiction

51 approval records across 2 jurisdictions, including tumor-agnostic approvals.

openfdaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Trastuzumab Deruxtecan	US FDA	Tumor-agnostic	HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )accelerated	approved	Dec 20, 2019	openfda

Data updated 12 hours agoSource updated unknown

Curated evidence

Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.

Therapy	Evidence items (count)	Sensitivity / response
Olaparib	15	15
Enzalutamide	6	6
Talazoparib	6	6
Rucaparib	4	4
Abiraterone	1	1
Niraparib	1	1

Curated Items are counted regardless of level or direction; see the evidence tab for the detail.

Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.